Shane M. Cooke is the CEO of Alkermes Inc. plc, a biopharmaceutical company specializing in drug development. He stepped into his leadership role on March 30, 2018. Before that, he had an impressive career as President of Alkermes Pharma Ireland...

Shane M. Cooke is the CEO of Alkermes Inc. plc, a biopharmaceutical company specializing in drug development. He stepped into his leadership role on March 30, 2018. Before that, he had an impressive career as President of Alkermes Pharma Ireland Limited and as Chief Financial Officer at Elan Corporation, which showcases his strong background in finance and operations. Cooke has significant experience in managing companies within the pharmaceutical industry, and he is a chartered accountant. Under his leadership, Alkermes has focused on developing innovative treatment options, particularly in the fields of addiction and mental health. In 2023, Cooke's compensation totaled approximately $9.44 million, driven mainly by performance-based stock awards that reflect the company's success. His strategic insights are fueled by a rich history in business development and a solid grasp of the regulatory landscape in the pharmaceutical sector. He also chairs the boards of multiple healthcare firms, which shows his extensive network and influence in this industry. Cooke's commitment to aligning executive interests with shareholder success is evident in his performance metrics, which center around the company’s growth and efficiency.